Steward Partners Investment Advisory
JSPR icon

Steward Partners Investment Advisory’s Jasper Therapeutics JSPR Stock Holding History

Steward Partners Investment Advisory’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35
Closed -$634 – 3353
2023
Q1 		$634 Buy
+35
New +$647 ﹤0.01% 3156

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Steward Partners Investment Advisory's JSPR Position: Q2 2023 in Review

Steward Partners Investment Advisory sold out of Jasper Therapeutics (JSPR) in Q2 2023, closing a stake of 35 shares — an estimated $634 sold.

Steward Partners Investment Advisory first reported a position in JSPR in Q1 2023 and held it in 1 quarter. The position peaked at $634 in Q1 2023. 46 funds tracked by Wall St. Rank hold JSPR as of Q2 2023.

  • Steward Partners Investment Advisory reported no remaining Jasper Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 35 Jasper Therapeutics shares in Q2 2023, an estimated $634.
  • Steward Partners Investment Advisory first reported a position in Jasper Therapeutics in Q1 2023 and held it in 1 quarter.
  • Steward Partners Investment Advisory's Jasper Therapeutics position peaked at $634 in Q1 2023.
  • 46 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2023, filed 14 Aug 2023.